Bayer CEO Anderson: AI Won't Cut Drug Development to 3 Years; Confident in 2027 Turnaround

• Bayer CEO Bill Anderson warns AI won't reduce drug development from 15 years to 3, citing long clinical trials.
• AI is used for molecular design, computational chemistry, and biology to improve early research success rates.
• Bayer is not entering the GLP-1 obesity drug market, focusing instead on climate-resilient agriculture and next-generation therapies.
• Anderson expects a visible turnaround by 2027, following a major corporate restructuring and management overhaul.
• Company's next big bets include direct-seeded rice for water reduction and a promising stem-cell therapy for Parkinson's disease.